ReviewKorean circulation journal2022
Reimbursement of Digital Therapeutics: Future Perspectives in Korea.
Review in Korean circulation journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Digital Therapeutic for Hwa-Byung (Korean Culture-Related Anger Syndrome) Based on Acceptance and Commitment Therapy: A Pilot Feasibility Trial.Healthcare (Basel, Switzerland) · 2026Article
- Piloting Digital Navigators to Promote Acceptance and Engagement With Digital Mental Health Apps in German Outpatient Care: Protocol for a Multicenter, Single-Group, Observational, Mixed Methods Interventional Study (DigiNavi).JMIR research protocols · 2025Article
- Approved trends and product characteristics of digital therapeutics in four countries.NPJ digital medicine · 2025Article
- Unpacking Performance Factors of Innovation Systems and Studying Germany's Attempt to Foster the Role of the Patient Through a Market Access Pathway for Digital Health Applications (DiGAs): Exploratory Mixed Methods Study.Journal of medical Internet research · 2025Article
- Core elements of national policy for digital health technology evidence and access.NPJ digital medicine · 2024Article
- Revolutionizing Healthcare: The Future of Wearable Single-Lead ECG Monitoring System.Korean circulation journal · 2024Article
- The New Emerging Treatment Choice for Major Depressive Disorders: Digital Therapeutics.Advances in experimental medicine and biology · 2024Review
- Stakeholders' Perceptions Regarding Digital Therapeutics Reimbursement in South Korea: Qualitative Study.JMIR mHealth and uHealth · 2023Article
- Digital Health Reimbursement Strategies of 8 European Countries and Israel: Scoping Review and Policy Mapping.JMIR mHealth and uHealth · 2023Article
- Mapping Factors That Affect the Uptake of Digital Therapeutics Within Health Systems: Scoping Review.Journal of medical Internet research · 2023Article
- The Beginning of the Era of Digital Therapeutics in Korea: Challenges and Opportunities.Journal of Korean medical science · 2023Article
- Diagnostic Ability of a Smartphone App for Dry Eye Disease: Protocol for a Multicenter, Open-Label, Prospective, and Cross-sectional Study.JMIR research protocols · 2023Article
- A Bibliometric Analysis of Research into Internet Gaming Disorders in Korea.International journal of environmental research and public health · 2023Review
- Rapid transition to digital healthcare and the role of oral and maxillofacial surgeons.Journal of the Korean Association of Oral and Maxillofacial Surgeons · 2022Article
- Digital health reimbursement: A scoping review of global lessons and policy implications.Digital healthReview
- Divergent Regulatory and Reimbursement Pathways for Digital Therapeutics: A Scoping Review With Implications for Korea.Inquiry : a journal of medical care organization, provision and financingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Digital health is rapidly growing worldwide and its area is expanding from wellness to treatment due to digital therapeutics (DTx). This study compared DTx in the Korean context with other countries to better understand its political and practical implications. DTx is generally the same internationally, often categorized as software as a medical device. It provides evidence-based therapeutic interventions for medical disabilities and diseases. Abroad, DTx support entailed state subsidies and fundraising and national health insurance coverage. In the case of national health insurance coverage, most cases were applied to mental diseases. Moreover, in Japan, DTx related to hypertension will possibly be under discussion for national health insurance coverage in 2022. In overseas countries, coverage was decided only when the clinical effects were equivalent to those provided by existing technology, and in the UK, real usage data for DTx and associated evaluations were reflected by national health coverage determination. Prices were either determined through closed negotiations with health insurance operating agencies and manufacturers or established based on existing technology. Concerning the current situation, DTx dealing with various diseases including hypertension are expected to be developed near in the future, and the demand for use and compensation will likely increase. Therefore, it is urgent to define and prepare for DTx, relevant support systems, and health insurance coverage listings. Several support systems must be considered, including government subsidies, science/technology funds, and health insurance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.